rs34637584, LRRK2

N. diseases: 78
Disease: Primary malignant neoplasm ×
Source: ALL
Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
Primary malignant neoplasm
CUI: C1306459
Disease: Primary malignant neoplasm
0.050 GeneticVariation BEFREE Furthermore, the aberrant neural pluripotency is consistent with Parkinson's pathophysiology and with the epidemiological association between the G2019S genotype and cancer risk. 31373835 2020
Primary malignant neoplasm
CUI: C1306459
Disease: Primary malignant neoplasm
0.050 GeneticVariation BEFREE Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). 31348549 2019
Primary malignant neoplasm
CUI: C1306459
Disease: Primary malignant neoplasm
0.050 GeneticVariation BEFREE This multinational study from 5 centers demonstrates that LRRK2 G2019S mutation carriers have an overall increased risk of cancer, especially for hormone-related cancer and breast cancer in women. 25401981 2015
Primary malignant neoplasm
CUI: C1306459
Disease: Primary malignant neoplasm
0.050 GeneticVariation BEFREE There was no increased association between G2019S or R1441G mutations and any type of cancer. 24357540 2014
Primary malignant neoplasm
CUI: C1306459
Disease: Primary malignant neoplasm
0.050 GeneticVariation BEFREE LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. 20818610 2010